Wegovy Pill Success:: First-quarter sales of the Wegovy pill reached 2.26 billion Danish kroner, significantly exceeding analyst estimates of 1.16 billion kroner.
Increased Guidance:: Novo Nordisk now anticipates adjusted sales and profit to contract between 4% and 12%, an improvement from the previously projected decline of 5% to 13%.
Market Dominance:: Wegovy currently holds 65% of new prescriptions in the U.S., positioning it as a leader in the weight-loss market.
Competition:: Despite competition from Eli Lilly's Foundayo, Wegovy pill sales are growing by double digits.
Synergistic Effect:: Both the injectable and oral versions of Wegovy are being utilized, creating a synergistic effect rather than cannibalization.
Novo Nordisk's Q1 2026 earnings reveal a significant impact from its Wegovy pill, driving overall sales and boosting investor confidence. The company's first-quarter sales jumped 32% on a constant currency basis, reaching 96.8 billion Danish kroner ($15.2 billion). Operating profit surged 65% to 59.6 billion kroner. While adjusted sales fell 4% and profits fell 6% due to a one-off provision reversal, the underlying performance of Wegovy is a clear highlight.
The Wegovy pill, launched in the U.S. in early January, has quickly gained traction, amassing 1.3 million prescriptions in the first three months. CEO Mike Doustdar notes that the pill is well-tolerated by patients and is experiencing double-digit growth despite competition. This early success is a welcome boost for Novo, which has faced setbacks in the past year, including disappointing trial results for its next-generation drug, CagriSema.
Novo and Eli Lilly are engaged in a fierce battle for market share in the lucrative weight-loss market, projected to reach $100 billion by the end of the decade. While Lilly has overtaken Novo in the U.S. market for injectable diabetes and weight loss drugs, Novo's Wegovy pill is off to a strong start. Lilly's CEO, David Ricks, acknowledges that the ramp-up of Foundayo will take time, giving Wegovy a competitive edge.
Actionable Takeaways:
Monitor the growth of Wegovy pill sales as it expands outside the U.S. in the second half of 2026.
Keep an eye on the competitive landscape as Eli Lilly continues to push its weight-loss drugs, particularly Foundayo.
Investors should note that analysts have flagged difficulties in predicting prescriptions and sales of these weight loss drugs, so consider this when evaluating the companies.
What is Wegovy?
Wegovy is Novo Nordisk's brand name for semaglutide, a GLP-1 receptor agonist, used for chronic weight management.
How does the Wegovy pill compare to the injectable version?
Both versions are being used, creating a synergistic effect. Clinical trials have shown the oral version may lead to more weight loss on average.
What is the competitive landscape like?
Novo Nordisk and Eli Lilly are the primary competitors in the weight-loss market, each offering injectable and oral medications.
Novo Nordisk's strong performance in Q1 2026, driven by Wegovy pill sales, signals a positive outlook for the company. The increased guidance and market dominance of Wegovy underscore its potential in the growing weight-loss market. Readers should monitor the competitive dynamics between Novo Nordisk and Eli Lilly and consider the challenges in predicting prescriptions and sales of these drugs.
Do you think this trend will last? Let us know!
Share this article with others who need to stay ahead of this trend!
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer